Lexaria Bioscience Corp. Warrant - LEXXW STOCK NEWS

Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.

Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.

05/06/2024 09:05 AM

News

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

Rhea-AI Summary

Lexaria Bioscience Corp. announces a research program with the National Research Council of Canada to evaluate DehydraTECH-GLP-1 drugs. The program will assess the molecular characteristics of semaglutide processed with DehydraTECH and its performance in simulated gastric conditions. The partnership aims to accelerate the integration of DehydraTECH with GLP-1 drugs into the pharmaceutical industry. Testing methods include PAGE, SEC, MALDI MS, and DLS to study the oligomerization potential of DehydraTECH-processed semaglutide. Initial results show increased peak levels of semaglutide in blood with reduced adverse events and improved blood sugar control compared to unprocessed Rybelsus® tablets.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.95%

Tags

04/30/2024 03:40 PM

News

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) announces a warrant exercise agreement with an investor, resulting in $4.7 million in gross proceeds. The company will issue new warrants at $4.75 per share, extending its operational runway into 2025. The funds will be used for working capital and general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25.61%

Tags

04/16/2024 09:10 AM

News

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) receives approval from an ethics review board to commence a new GLP-1 study. The study will investigate the effectiveness of DehydraTECH-enabled semaglutide formulations in comparison to Rybelsus®. The company aims to improve drug delivery and blood glucose control through this study.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16.08%

Tags

04/02/2024 09:00 AM

News

Lexaria Awarded New Patents

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) receives new patents in epilepsy and anti-viral agents, enhancing drug delivery platforms. The company obtained two patents for treating epilepsy in the USA, showcasing effectiveness in mitigating seizures. Additionally, a patent in Japan for enhanced delivery of antiviral agents was granted. Lexaria now holds 41 patents globally, reinforcing its intellectual property portfolio.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.46%

Tags

03/14/2024 09:20 AM

News

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Rhea-AI Summary

Lexaria Bioscience Corp. appoints Nelson Cabatuan as Chief Financial Officer to drive long-term growth strategy. Mr. Cabatuan brings over 15 years of corporate finance experience in the life sciences industry, enhancing Lexaria's financial operations and potential use of DehydraTECH platform for therapeutic applications.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12.5%

Tags

03/07/2024 09:05 AM

News

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Rhea-AI Summary

Lexaria Bioscience Corp. announces the initiation of a human pilot study to test the first-ever dissolvable DehydraTECH-GLP-1 oral dose formulation, aiming to revolutionize GLP-1 drug delivery. The study will compare three dose formulations, including a positive control Rybelsus® semaglutide swallowed tablet, DehydraTECH-semaglutide swallowed capsules, and an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. If successful, this innovative delivery method could eliminate the need for painful injections or stomach-upsetting tablets.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.61%

Tags

03/05/2024 09:05 AM

News

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

Rhea-AI Summary

Lexaria Bioscience Corp. announces an 8-week animal study to examine the effects of DehydraTECH-processed GLP-1 and CBD formulations on weight loss and blood glucose control. The study will assess brain absorption delivery enhancement and potential benefits for diabetes treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12.67%

Tags

03/04/2024 09:15 AM

News

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Rhea-AI Summary

Lexaria Bioscience Corp. announces positive results from a study on its DehydraTECH-CBD formulation, showing weight loss and blood glucose reduction in rodents. The company is progressing to a large animal study and has also reported promising results in a human study. Lexaria aims to further investigate the potential benefits of its formulations for weight loss and blood glucose control.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.74%

Tags

03/01/2024 08:20 AM

News

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) receives FDA confirmation for IND application, paving the way for a Phase 1b hypertension clinical trial utilizing DehydraTECH-CBD. The milestone achievement demonstrates the technology's efficacy and safety, positioning Lexaria for potential future pharmaceutical commercialization.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-15.36%

Tags

02/16/2024 04:05 PM

News

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Rhea-AI Summary

Lexaria Bioscience Corp. successfully closes a registered direct offering, raising approximately $3.6 million for research and development studies, patent costs, and general working capital. The offering includes the sale of 1,558,443 shares of common stock and unregistered warrants to purchase additional shares at a purchase price of $2.31 per share and an exercise price of $2.185 per share, respectively.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.41%

Tags

FAQ

What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?

The current stock price of Lexaria Bioscience Warrant (LEXXW) is $0.7484 as of November 22, 2024.

What is Lexaria Bioscience Corp. known for?

Lexaria Bioscience Corp. is known for its patented drug delivery technology, DehydraTECH, which enhances the absorption of active pharmaceutical ingredients.

In which segments does Lexaria operate?

Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate.

What are the key benefits of DehydraTECH?

DehydraTECH has shown to increase bio-absorption, reduce onset times, and mask unwanted tastes of active pharmaceutical ingredients.

What is the main goal of Lexaria Bioscience Corp.?

Lexaria aims to revolutionize drug delivery methods and improve outcomes through ongoing research and innovation.

How does DehydraTECH impact drug delivery across the blood-brain barrier?

DehydraTECH has evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, which is crucial for centrally active compounds.

What is the significance of Lexaria's intellectual property portfolio?

With 43 patents granted worldwide, Lexaria's intellectual property portfolio plays a key role in supporting its future business objectives.

Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?

GLP-1 drugs like Rybelsus and Ozempic are owned and manufactured by Novo Nordisk.

What is the focus of Lexaria's ongoing research?

Lexaria's ongoing research aims to validate the effectiveness of DehydraTECH in delivering various active pharmaceutical ingredients orally and improving tolerability.

How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?

Lexaria's latest Study aims to evaluate the absorption and effectiveness of DehydraTECH-processed tirzepatide in an oral dosage format, potentially offering improved tolerability and measurable drug levels in the bloodstream.

What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?

Lexaria's focus on enhancing drug absorption, reducing onset times, and addressing taste issues sets it apart as a leading innovator in drug delivery platforms.